


The contents of this file are password protected. The copy is protected by copyright of the Author. Consent has been given for the express purpose of educating attendees of the March 2009 registrars' conference in Melbourne.

You **MAY NOT COPY OR DISTRIBUTE** the contents or images in any form.

You **MAY PRINT** the document for your own personal use as an educational resource.



ORAL CAVITY TUMOURS

Eduard I. Pudel MBBS FRACS

Otorhinolaryngologist, Head and Neck Surgeon

Chairman, Head and Neck Tumour Stream, VCOG, TCCV


VMO: Royal Melbourne Hospital

VMO: Monash Medical Centre

Private Practice: Brighton

11 March 2009

ORAL CAVITY



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

SUBSITES OF ORAL CAVITY

- Lip
- Buccal mucosa
- Lower alveolar ridge
- Upper alveolar ridge
- Retromolar trigone
- Floor of mouth
- Hard palate
- Oral Tongue
 - (ie anterior 2/3, demarcated by circumvallate papillae)



Other lesions of mouth

- ▶ Torus palatinus and torus mandibularis
- ▶ Lingual thyroid
- ▶ Developmental cysts (eg dermoid, duplication, nasoalveolar)
- ▶ Fibroma (aka FEP – Fibroepithelial Polyp)
- ▶ Pyogenic Granuloma
- ▶ Ulcerations (aphthous, lichen planus, pemphigus, pemphigoid, Behcet's)
- ▶ Necrotising Sialometaplasia
- ▶ Infections (fungal, viral, bacterial)



BENIGN TUMOURS

- ▶ Papilloma
- ▶ Granular Cell Tumour
- ▶ Neurofibroma
- ▶ Lipoma
- ▶ Haemangioma
- ▶ Ameloblastoma
- ▶ Pleomorphic Adenoma



Suspicious Lesions

▶ LEUKOPLAKIA

▶ Usually:

▶ lower grade dysplasia vs higher grade dysplasia

ERYTHROPLASIA




© Elsevier 2005



© Elsevier 2005

PROGRESSION TO CARCINOMA



© Elsevier 2005

EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

MALIGNANCIES

- **Squamous Cell Carcinoma**
- Verrucous Carcinoma
- Mucoepidermoid Carcinoma
- Acinic Cell Carcinoma
- Adenoid Cystic Carcinoma
- Malignant Melanoma
- Sarcomas (eg Osteo, Kaposi's etc)
- Lymphoma

SQUAMOUS CELL CARCINOMA



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

SQUAMOUS CELL CARCINOMA



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

SQUAMOUS CELL CARCINOMA



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

SQUAMOUS CELL CARCINOMA



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

SQUAMOUS CELL CARCINOMA



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

MULTIDISCIPLINARY TEAM

ALL Head and Neck Malignancies Should be managed through a multidisciplinary team:

Head and Neck Surgeons:

- Otorhinolaryngologist Head and Neck Surgeon (HN training)
- General Surgeon with HN training
- Plastic Reconstructive Surgeon with HN training
- OMF Surgeon with HN training

Radiation + Medical Oncologists


Radiologist

Pathologist

Speech Pathologist

Dietitian/Physio/OT

Nursing Staff



ANZ Head & Neck Society

Workup of a HNC patient

- ▶ History and Examination (see below)
- ▶ Ix:
- ▶ Biopsy of primary lesion if easily accessible & LA
- ▶ CT neck + chest + Contrast
- ▶ OPG
- ▶ U/S tongue (frequently these days)
- ▶ Commonly MRI
- ▶ Most times PET/CT
- ▶ Usually USG FNAC
- ▶ Panendoscopy + Biopsies

Demographics etc

- ▶ Oral ca. accounts for 3% of all cancer deaths.
- ▶ Males are approximately twice as likely as females to be diagnosed with and to die from oral cancer.
- ▶ 90% of oral cancer cases occur among persons over 45 years of age, and the average age of diagnosis is 60 years.
- ▶ Oral cancers are the sixth most common cancer
- ▶ Five-year relative cancer survival rates 56%
- ▶ 90% oral cancers are SCC
- ▶ 5% are salivary gland malignancies,
- ▶ 5% melanomas, sarcomas, and lymphomas


Hx: PREDISPOSING FACTORS

- Known risk factors for squamous cell carcinoma:
 - long-term tobacco use
 - alcohol use
 - immunosuppression
 - use of the betel (areca) quid
 - long-term sun exposure
 - recent studies indicate infection with human papillomavirus (eg oral sex)



Examination of Oral Cavity

- ▶ Adequate light,
- ▶ 2x tongue depressors
- ▶ Tongue
 - Movement
 - Lateral aspect
 - Dorsal surface
- ▶ Floor of mouth
- ▶ Palate
- ▶ Teeth
- ▶ **BIMANUAL PALPATION!!!!**
- ▶ **SALIVARY DUCTS**



COMPLETE Examination

- Complete ENT examination
 - Skin, oral cavity, oropharynx, nose, ears, neck, nerve Fn & sens-n
- Flexible Fibreoptic nasopharyngolaryngoscopy



FINE NEEDLE ASPIRATION

COMMONLY UNDER U/S

Fast

Minimally invasive


Cheap

Sensitive

Few complications



Follicular lymphoma



EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

Cancer Staging – TNM




- ▶ Spread of carcinoma
 - Local invasion
 - Lymphatic spread
 - Haematogenous spread
- ▶ TNM classification
 - T – local invasion
 - N – lymph node involvement
 - M – metastatic spread
 - Lung, Liver, Bone

TNM STAGING (AJCC)

- ▶ Tx: primary cannot be assessed
- ▶ T0: No evidence of Primary
- ▶ Tis: Ca in situ
- ▶ T1: Tumour 2cm or less in greatest dimension
- ▶ T2: >2 but NOT MORE than 4cm (ie inclusive)
- ▶ T3: More than 4 cm
- ▶ T4 (lip): through cortical bone, IAN, FOM, skin of chin or nose
- ▶ T4a: through cortical bone, Deep (extrinsic) m of tongue, Maxillary sinus, skin of face
- ▶ T4b (unresectable): masticator space, pterygoid plates, skull base, encases ICA, prevertebral muscles
- ▶ (NB: superficial alveolar erosion of alveolar tumour isn't enough for T4)

N – Nodal Disease



- ▶ 200 nodes in head/neck
- ▶ Malignant disease in head and neck follows predictable drainage patterns
- ▶ Malignant disease almost always spreads to local lymph nodes prior to distant metastasis



TNM STAGING

Nodal Staging:

Nx: not assessed

N0: No regional cervical lymph node mets

N1: Single ipsilateral node 3cm OR LESS

N2a: Single ipsi node more than 3cm but not more 6cm

N2b: Multiple ipsi nodes “

N2c: Contralateral or bilateral nodes none >6cm

N3: Metastasis MORE THAN 6cm in lymph nodes

Metastatic Staging

Mx (not worked up yet)

M0: no distal mets

M1: any mets outside the neck

STAGE GROUPING

- ▶ STAGE 0: T_{is} N0M0
- ▶ STAGE I: T1 N0M0
- ▶ STAGE II: T2 N0M0
- ▶ STAGE III: T3 N0M0 (OR T1–3 N1M0 *?stage II)
- ▶ STAGE IVa: T4a N0–1M0 OR T1–4a N2M0
- ▶ STAGE IVb: T4b N0–3 M0 OR any T N3 M0
- ▶ STAGE IVc: any T any N M1
- ▶ *NB: The AJCC calls an N1 as stage III, but in practice we treat some T1–2 N1 like Stage II

Mx according to stage

- ▶ Stage I–II usually single modality Rx, unless adverse features: see below
- ▶ Stage III–IV: usually combined modality Rx

Other important features:

- ▶ Tumour thickness (eg if tongue SCC is thicker than 7mm, it's XRT anyway)
- ▶ Perineural invasion
- ▶ Lymphovascular invasion of primary
- ▶ Close <5mm / Positive Margins
- ▶ Extracapsular spread (nodal disease)

- ▶ These are usually identified
- ▶ POST RESECTION
- ▶ But sometimes ESTIMATED from imaging

Treatment Options


- ▶ Surgery
- ▶ Radiotherapy (XRT)
- ▶ Chemotherapy
- ▶ COMBINATION THERAPY

Radiotherapy – Principles

- ▶ Cells killed in mitosis
- ▶ Cancer cells divide more frequently
- ▶ Malignant cells repair less efficiently
- ▶ Selective destruction of neoplastic cells

Complications of XRT

- ▶ Skin reaction
 - sunburn / tan
- ▶ Mucositis – damage to mucos membrane
 - Pain, odynophagia, weight loss, anorexia
- ▶ Xerostomia
 - Dry mouth
- ▶ Osteoradionecrosis
- ▶ Long term
 - Dry mouth, poor wound healing
 - Can only be given once
 - 10% chance of developing cancer due to treatment
 - Damage to vital structures
 - Brain, spinal cord, eye



Chemotherapy

- ▶ Limited role to play in management of head and neck cancers as a sole modality
- ▶ Used together with other modalities

Decision to Operate



- ▶ Cure for some
- ▶ Local control for others
- ▶ Sometimes the most difficult but wisest decision is for non-operative palliation

Surgery

- ▶ Stage disease
 - Local tumour – size / function
 - Nodal disease
 - 2nd primary
- ▶ Remove tumour with surrounding cuff of normal tissue: 5mm margin or greater
- ▶ Replace defect with appropriate reconstructive surgery (flaps / grafts)
- ▶ Surgery for nodal disease if necessary: Neck dissection

Neck Dissection

- ▶ Palpable metastatic nodes in the neck, radiologic +/- FNA proven disease:
 - ▶ usually Comprehensive ND (I-V)
- ▶ High likelihood of occult secondaries in neck, without palpable disease,
- ▶ *But how do we decide when to dissect elective N0 necks?*

TUMOUR THICKNESS (Patel et al 2009):

- ▶ No patient with tumour thickness $\leq 2\text{mm}$ had nodal mets
- ▶ 40% with tumours $>2\text{mm}$
- ▶ Using the 5mm cut off:
- ▶ 19% nodal mets $\leq 5\text{mm}$ vs 44% $>5\text{mm}$
- ▶ Using Weiss' principle of elective neck dissection with 20% or more risk, the 5mm cut off appears appropriate

Tumour Thickness (Jalisi 2005)

- ▶ T1 /2 FOM with thickness $\leq 1.5\text{mm}$ is safe to observe rather than neck dissection (they found that thickness of 1.6–3.5 mm correlated with 33% of cervical mets, and 60% of cases 3.6mm and greater)
- ▶ T1 /2 Oral tongue $< 4\text{ mm}$ is safe to observe
- ▶ T1 /2 Lip carcinomas

- ▶ **ANYTHING ELSE IN ORAL CAVITY GETS A ND**


ND, BUT WHICH LEVELS?

- ▶ Ipsilateral SOHND (supraomohyoid Neck Dissection) Ia, Ib, IIa, IIb, III: standard care if dissecting an N0 neck for oral SCC
- ▶ Level IV: Byers et al report skip mets of 15% to level IV WITHOUT other level involvement in oral tongue that warrants a neck dissection
- ▶ CONTROVERSY PERSISTS HERE: some dissect Level IV in all oral SCC necks
- ▶ SOME SAY dissect I–IV if I looks suspicious rather than doing I–V even

SHOULD WE DISSECT THE CONTRALATERAL NECK?

- ▶ 14% INCIDENCE OF CONTRALATERAL DISEASE REGARDLESS OF TUMOUR STAGE, SO
- ▶ CURRENT RECOMMENDATION IS FOR CONTRALATERAL NECK DISSECTION WITH CARCINOMA INVOLVING MIDLINE, BILATERAL OR TONGUE TIP (WITHIN 2CM)

Tracheostomy




EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON

Tracheostomy: some are tricky



Reconstructive algorithm



Long Term Problems Post Major Head and Neck Surgery

- ▶ Deformity
- ▶ Speech
- ▶ Swallowing (aspiration)
- ▶ Emotional / social aspects

Seven Warning Signs for Head & Neck Cancer


1. Change in mole or new skin lesion
2. Non-healing mouth ulcer
3. Change in denture fit
4. Hoarseness
5. Persistent throat / ear pain
6. Neck lump
7. Unilateral nasal obstruction or bleeding

SALIENT POINT

- ▶ MOST ORAL CAVITY CANCERS ARE TREATED WITH SURGERY +/- XRT OR CHEMORT AS A PRIMARY MODALITY
- ▶ ON THE OTHER HAND MOST OROPHARYNGEAL MALIGNANCIES ARE TREATED WITH XRT / CHEMORT AS THE PRIMARY MODALITY AFTER ADEQUATE STAGING

References used:

- ▶ RCSI lecture series
- ▶ UTMB lecture series
- ▶ Bailey + Cummings textbooks of ORL HNS
- ▶ AJCC Cancer Staging Handbook, 6th edn 2002
- ▶ Salient articles:
 - ▶ Patel RS et al. Prognostic Factors in the surgical treatment of patients with oral carcinoma. ANZJSurg 79 (2009) 19–22
 - ▶ Noonan VL and Kabani S. Diagnosis and Management of Suspicious Lesions of The Oral Cavity. Otolaryn Clin N Am 38 (2005) 21–35
 - ▶ Jalisi S. Management of the Clinically Negative Neck in Early Squamous Cell Carcinoma of the Oral Cavity. Otolaryn Clin N Am 38 (2005) 37–46
- ▶ AND REFERENCES TO THOSE ARTICLES



questions?

EDUARD I PUDEL
OTORHINOLARYNGOLOGIST HEAD
& NECK SURGEON